Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today the completion of a further technological milestone in the manufacture of its first LIGHT system.
Delivery of CCLs
The Company confirms that the final Coupled Cavity Linac (CCL) module, to be used to generate a beam capable of treating superficial tumours when integrated with the LIGHT system’s other components, is ready for shipment to the Geneva testing facility; the other CCL modules are on site.
The CCLs are an integral component of LIGHT and are the final accelerating structures after the proton source, the Radio Frequency Quadrupole (“RFQ”) and Side Coupled Drift Tube Linacs (“SCDTLs”). The CCLs will undergo further testing before being conditioned and prepared for integration with the SCDTLs in 2018.
The LIGHT system’s development remains on track for LIGHT to produce a proton beam capable of treating superficial tumours by the end of Q3 2018, with the beam expected to be fired through the first CCL by the end of Q2 2018. Work continues on the integration of the SCDTLs with the RFQ, with the first beam through the SCDTLs expected by the end of the year.
The integration of the components that will form the Patient Positioning System continues apace and is also expected to advance significantly in the coming months.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy Plc, said: “The successful manufacture, performance testing and now delivery of the CCLs are a major milestone in the technological development of the LIGHT system. For the first time, we will now have all of the key high-speed accelerating modules for LIGHT in place in our Geneva site and with a great deal of the manufacturing risk behind us, we can focus on the integration and commissioning of the individual components. This development brings the reality of the world’s first linear proton accelerator in the treatment of cancer much closer.”
